• Biome Her™ Pessary for vaginal microbiome balance
• Biome Perinatal™ Probiotic for healthy pregnancy and postpartum
• Clinically-trialled probiotic strains to support women's health

Biome Australia Limited (ASX: BIO) is pleased to announce the launch of two new products in its Activated Probiotics range, supporting women's health. The first is Biome Her™ Pessary, a vaginally-inserted probiotic product containing clinically-trialled strains Lactobacillus acidophilus LA02 and Lactobacillus fermentum LF10 that have been shown to reduce recurrence rates of vaginal thrush. This product will complement the existing Biome Her™ Probiotic oral supplement. The second new product is Biome Perinatal™ Probiotic, formulated with clinically-trialled strains including Lactobacillus rhamnosus HN001 that have demonstrated benefits for healthy pregnancy, maternal health, and postpartum mood balance. With women's health being the top-selling supplements category in Australia, and prenatal vitamin sales reaching $98.6 million in 2024, these new targeted probiotic products aim to better support women through key life stages. Biome is committed to providing innovative, evidence-based natural medicines to healthcare practitioners and consumers.

Biome expects strong demand for its new Biome Her™ Pessary and Biome Perinatal™ Probiotic products, which are targeting the growing women's health supplements market in Australia and internationally. The company has not provided any specific financial guidance for these new product launches.

Biome is focused on expanding its range of evidence-based probiotic and complementary medicine products to address key health needs, particularly in the growing women's health category. The company sees significant opportunities to support women through all life stages, from vaginal health to pregnancy and postpartum care.